Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of the Claims
Per Applicant’s amendment to the claims, submitted on 01/28/2025, claims 1-81 are canceled, and claims 82-104 are newly added. Currently, claims 82-104 are pending in the instant application.
Priority
The instant application is a CON of application 17/560,048 filed on 12/22/2021 which has been issued as US Patent No. 12152028. The instant application claims foreign priority to PCTCN2020139524 filed on 12/25/2020.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 82-104 rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1-41 of U.S. Patent No. 12152028. Although the claims at issue are not identical, they are not patentably distinct from each other because they are essentially directed towards the same subject matter.
Claim 82 of the instant application recites a composition comprising:
A composition comprising:
A compound of Formula Ia in an amount of at least 99% w/w:
PNG
media_image1.png
197
258
media_image1.png
Greyscale
And one or more impurity in an amount of from 0.01 to 1% w/w
One or more pharmaceutically acceptable excipients
Claim 87 of the instant application recites the composition of claim 82 wherein the impurity further comprises a compound of formula X-Da in an amount less than 0.40% w/w
PNG
media_image2.png
199
265
media_image2.png
Greyscale
And a compound of formula X-Ea in an amount of less than 0.40% w/w
PNG
media_image3.png
196
271
media_image3.png
Greyscale
Claim 97 of the instant application recites a method of treating a disorder or condition through modulating a glucocorticoid receptor, comprising administering to a subject in need of such treatment, a therapeutically effective amount of a pharmaceutical composition of claim 82.
Claim 98 of the instant application recites a method of treating a disorder or condition through antagonizing a glucocorticoid receptor, comprising administering to a subject in need of such treatment, a therapeutically effective amount of a composition of claim 82.
Claim 99 of the instant application recites a method of treating fatty liver disease, comprising administering to a subject in need thereof, a therapeutically effective amount of a composition of claim 82.
Claim 104 of the instant application recites a method of treating antipsychotic induced weight gain, comprising administering to a subject in need thereof, a therapeutically effective amount of a composition of claim 82.
Claim 33 of the ‘028 patent recites a composition comprising a compound of Formula I in an amount of at least 99% w/w:
PNG
media_image4.png
293
338
media_image4.png
Greyscale
And one or more impurity in an amount from 0.01 to 1% w/w.
Claim 37 of the ‘028 patent recites a pharmaceutical composition comprising a composition of claim 33, and one or more pharmaceutically acceptable excipients.
Claim 38 of the ‘028 patent recites a method of treating a disorder or condition through modulating a glucocorticoid receptor, comprising administering to a subject in need of such treatment, a therapeutically effective amount of a composition of claim 33, thereby treating the disorder or condition.
Claim 39 of the ‘028 patent recites a method of treating a disorder or condition through antagonizing a glucocorticoid receptor, comprising administering to a subject in need of such treatment, a therapeutically effective amount of a composition of claim 33, thereby treating the disorder or condition.
Claim 40 of the ’028 patent recites a method of treating fatty liver disease, comprising administering to a subject in need thereof, a therapeutically effective amount of a composition of claim 33, thereby treating fatty liver disease.
Claim 41 of the’028 patent recites a method of treating antipsychotic induced weight gain, comprising administering to a subject in need thereof, a therapeutically effective amount of the crystalline form of claim 33, thereby treating antipsychotic induced weight gain.
The claims of the instant application and the claims of the’028 patent appear to be drawn to essentially the same compositions and the same methods of use of said compositions. The claims of the ‘028 patent appear to also provide methods of making the compound utilized in the compositions. As can be seen above, claim 33 of the ‘028 patent recites a composition comprising the same compound recited in claim 82 of the instant application, and furthermore, in claim 37 recites a composition comprising said composition of claim 33 and one or more pharmaceutical excipients. Accordingly, claim 82 of the instant application and claim 27 of the ‘028 patent are directed towards essentially the same compositions. Furthermore, claims 97-99 and 104 of the instant application are directed towards the same methods of use as recited in claims 38-41 of the ’028 patent. As the claims at hand are essentially addressing the same compositions and methods of use, they cannot be considered as patentably distinct from one another.
Conclusion
Claims 82-104 are rejected.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to ERIC TRAN whose telephone number is (571)272-7854. The examiner can normally be reached Mon-Fri 8:00-5:00.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey S Lundgren can be reached at (571) 272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/ERIC TRAN/Examiner, Art Unit 1629
/JEFFREY S LUNDGREN/Supervisory Patent Examiner, Art Unit 1629